Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenazopyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | MAPT | P10636 | 8/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | HBB | P68871 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazopyridine SCHEMBL5948996 | 1.00 | MEN1 (0.77) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL18534 | 0.94 | MEN1 (0.82) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL7406346 | 0.91 | MEN1 (0.71) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL960940 | 0.89 | MEN1 (0.73) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL26499 | 0.88 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL28796595 | 0.88 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL215655 | 0.88 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL29392321 | 0.88 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL14687482 | 0.88 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL19357 | 0.88 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833459-B2 | Reducing thiazole ester to thiazole alcohol using sodium borohydride in the presence of aluminum chloride in a solvent and oxidising the thiazole alcohol to obtain 4-methyl-5-formyl-thiazole | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2004-12-21 | — | — | US | claimed |
| US-5750794-A | Process for preparing chiral tetralone | PFIZER INC. (US) | 1998-05-12 | — | — | US | claimed |
| US-20230373954-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-23 | — | — | US | disclosed |
| US-11767311-B2 | Acid secretion inhibitor and use thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-09-26 | — | — | US | disclosed |
| EP-4212533-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | Cyclacel Limited (GB) | 2023-07-19 | — | — | EP | disclosed |
| US-20230192650-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230098332-A1 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | GIVAUDAN SA (CH) | 2023-03-30 | — | — | US | disclosed |
| EP-4148050-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-03-15 | — | — | EP | disclosed |
| EP-3573988-B1 | PROCESS FOR PREPARING PURINE DERIVATIVES | CYCLACEL LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| WO-2021256861-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | 일동제약(주) | 2021-12-23 | — | — | WO | disclosed |
| US-10927113-B2 | Process for preparing purine derivatives | CYCLACEL LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| EP-0145434-A2 | Novel dihydropyridine derivatives and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-4510331-A | ISOMERIZATION OF 2,7-OCTADIENE-1-OL USING A COPPER CHROMIUM AND/OR ZINC OXIDE CATALYST | KURARAY COMPANY, LTD. (JP) | 1985-04-09 | — | — | US | disclosed |
| EP-0113101-A1 | 6-(1-Hydroxyethyl)-2-SR8-1-methyl-1-carbadethiapen-2-em-3-carboxylic acid esters | MERCK & CO. INC. (US) | 1984-07-11 | — | — | EP | disclosed |
| EP-0069339-A2 | Process for producing 7-octen-1-al and derivatives thereof | KURARAY CO., LTD. (JP) | 1983-01-12 | — | — | EP | disclosed |
| US-4244874-A | ANTICARCINOGENIC AGENTS | BRISTOL-MYERS COMPANY (US) | 1981-01-13 | — | — | US | disclosed |
| US-4232036-A | 6-, 1- and 2-Substituted-1-carbadethiapen-2-em-3-carboxylic acids | MERCK & CO., INC. (US) | 1980-11-04 | — | — | US | disclosed |
| US-4218462-A | 6-(1-Hydroxyethyl)-2-(2-aminoethylthio)-1-substituted-1-carbade-thiapen-2-em-3-carboxylic acids | MERCK & CO., INC. (US) | 1980-08-19 | — | — | US | disclosed |
| US-4208422-A | ANTIBIOTICS, BACTERICIDES | MERCK & CO., INC. (US) | 1980-06-17 | — | — | US | disclosed |
| EP-0010317-A1 | 6-, 1- and 2-substituted-1-carbapen-2-em-3-carboxylic acids, processes for the preparation of such compounds and pharmaceutical composition comprising such compounds | MERCK & CO. INC. (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767311-B2 | Acid secretion inhibitor and use thereof | SLC10A2, SLC10A1, ASIC1 | MEN1 1938/4885KMT2A 3688/4885MAPT 4359/4885 |
| US-20230098332-A1 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | MEN1 3144/4885KMT2A 2737/4885MAPT 2450/4885 |
| US-10927113-B2 | Process for preparing purine derivatives | CTR9, PNP, C5 | MEN1 4360/4885KMT2A 4625/4885MAPT 4586/4885 |
| US-20230373954-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | SLC10A2, SLC10A1, ASIC1 | MEN1 2339/4885KMT2A 3786/4885MAPT 4517/4885 |
| US-20230192650-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | SLC10A2, SLC10A1, ASIC1 | MEN1 2339/4885KMT2A 3786/4885MAPT 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.